Secondary failure of oral hypoglycaemicagents: frequency, possible causes, andmanagement. Diabetes Metab Rev 1994;10:31–43 6. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonyl-urea, metformin, or insulin in patientswith type 2 diabetes mellitus: progres-sive requirement for multiple therapies(UKPDS 49). UK Prospective DiabetesStudy (UKPDS) Group. JAMA 1999;281:2005–2012 7. Edwards CM, Stanley SA, Davis R, Brynes AE, Frost GS, Seal LJ, Ghatei MA, BloomSR. Exendin-4 reduces fasting and post-prandial glucose and decreases energy in-take in healthy volunteers. Am J PhysiolEndocrinol Metab 2001;281:E155–E161 8. Nielsen LL, Young AA, Parkes DG. Phar- macology of exenatide (synthetic ex-endin-4): a potential therapeutic forimproved glycemic control of type 2 dia-betes. Regul Pept 2004;117:77–88 9. Buse JB, Henry RR, Han J, Kim DD, Fine-